文摘
摘要目的:本研究的目的是解决局部炎症活动的影响在大脑和视网膜损伤neuro-axonal女士。
背景:神经保护在多发性硬化症(MS)需要时间相互作用的正确认识炎症和神经退行性变的。
设计/方法:168年独联体或MS患者从MS-Visualpath队列(2011年2月- 2018年5月)评估资格。我们排除了九个,三十个参与者对于视网膜和大脑模型,分别由于缺乏后续的数据,疾病持续时间> 30年,可怜的图像质量。参与者接受神经系统、眼科、光学相干断层扫描(OCT)和磁共振成像(MRI)检查每年至多三年的随访和做一次。我们模拟动态视网膜变薄(视神经盘旁视网膜神经纤维layer-pRNFL -;神经节细胞+内网状layer-GCIPL -和内部核layer-INL)和脑容量损失(整个大脑,大脑灰质和丘脑)女士在整个课程。我们评估变更的影响当地的炎症活动(活动≥复发或病变)在视网膜和大脑疾病持续时间变化混合效应模型还包括年龄、性别、疾病修饰治疗方法的使用,使用类固醇(大脑)和以前的视神经炎(视网膜)。
结果:159名患者(110名(69.2%)妇女;中位数(四分位距差):40.7(33.7 - -48.8)岁)被包括在内。视网膜和大脑的变化更明显在所有疾病的5第一年估计除了INL常数在女士。与活跃的参与者显示女士大大增强GCIPL变薄(p = 0.002),整个大脑(p = 0.038)和丘脑(假定值= 0.001)体积损失比稳定的病人在第一个5年。此后,积极和稳定显示重叠率趋势稳定的女士neuro-axonal受伤。
结论:局部炎症活动规则神经退行性变的早期女士女士最好的神经保护策略为笼头炎症活动在第一年。其他方法可能探索神经退化曲线晚。
披露:Pulido Valdeolivas博士已经收到个人赔偿咨询、担任科学顾问委员会说,或其他活动与罗氏西班牙,Genzyme-Sanofi,光环创新的机器人。Pulido Valdeolivas博士已经收到赔偿服务董事会的光环创新的机器人。Pulido Valdeolivas博士已经收到版税,许可证费用,或从光环合同权利支付创新的机器人。Pulido Valdeolivas博士持有股票或股票期权在光环创新机器人科研博士Pulido Valdeolivas卷入作为调查员。Pulido Valdeolivas博士持有股票或股票期权的光环创新的机器人。Pulido Valdeolivas博士收到光环的研究支持创新的机器人。博士安道尔没有披露。Gomez-Andres博士已经收到个人赔偿咨询、担任科学顾问委员会说,或其他活动Idec, PTC,诺华,罗氏,夏尔。Gomez-Andres博士已经收到赔偿服务董事会的光环创新的机器人。Gomez-Andres博士已经收到版税、许可费或合同权利支付从光环创新的机器人。 Dr. Gómez-Andrés holds stock and/or stock options in Aura Innovative Robotics which sponsored research in which Dr. Gómez-Andrés was involved as an investigator. . Dr. Gómez-Andrés holds stock and/or stock options in Aura Innovative Robotics. Dr. Nakamura has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with NeuroRx Research and Sanofi Genzyme. Dr. Nakamura has received royalty, license fees, or contractual rights payments from license fee from Biogen Idec. Dr. Nakamura has received research support from Biogen Idec, Sanofi Genzyme, and Novartis. Dr. Alba-Arbalat has nothing to disclose. Dr. Lampert has nothing to disclose. Dr. Zubizarreta has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme, Biogen, Merck and Bayer-Schering. Dr. Llufriu has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis, Teva, Genzyme and Merck. Dr. Martinez-Heras has nothing to disclose. Dr. Solana has nothing to disclose. Dr. Sola-Valls has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi, Bayer-Schering, Novartis Pharmaceuticals, and Biogen. Dr. Sepúlveda has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme, Novartis Pharmaceuticals, and Biogen. Dr. Tercer-Uribe has nothing to disclose. Dr. Blanco Morgado has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis and Genzyme-Sanofi. Dr. Saiz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck-Serono, Sanofi, Biogen, Roche, TEVA, Novartis, and Bayer-Schering. Dr. Camos-Carreras has nothing to disclose. Dr. Sanchez-Dalmau has nothing to disclose. Dr. Villoslada has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche and Health Engineering. Dr. Villoslada has received compensation for serving on the Board of Directors of Bionure Inc, Spire Bioventures, Mint-Labs and Health Engineering. Dr. Martinez-Lapiscina has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with CIHR, Research Manitoba, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, Crohn’s and Colitis Canada, National Multiple Sclerosis Society, CMSC.
